Sid Kerkar, MD, on Developing CAR T Therapies Without Lymphodepletion Chemotherapy

Video

The vice president of oncology and research and development at Exuma Biotech discussed the company’s platforms, including CAR-TaNK cells.

“Currently, the biggest challenge is the time it takes to develop these treatments. The ability to manufacture cells in a day significantly decreases that time as well as the ability to do the release testing and to have a product ready in a week's time. That is a significant advance over the 3 to 4 weeks that it currently takes. That enables someone to get treatment without having to do bridging therapy... for oncology, for a disease that is rapidly dividing, people don't have that time, and it makes a big difference.”

Sid Kerkar, MD, vice president of oncology and research and development at Exuma Biotech, participated in a talk called “Subcutaneous generation of synthetic lymph nodes for the in vivo production of CAR-TaNK cells” at the 7th Annual CAR-TCR Summit 2022, held September 19-22 in Boston, Massachusetts.

CGTLive spoke with Kerkar to learn more about the chimeric antigen receptor T-cell natural killer (CAR-TaNK) cells being developed by Exuma Biotech to address current challenges with treating solid tumors. The therapy works by injecting CD3-directed lentiviral vectors loaded with peripheral blood mononuclear cells to form synthetic lymph nodes at the site of the injection that develop distinct CD3+ CD8+ CD56+ NKG2D+ CAR-TaNK cells. The therapy may allow for higher efficacy and lower toxicity, without the need for lymphodepletion chemotherapy. He also discussed other technology platforms in development at Exuma.

REFERENCE
Kerkar S. Subcutaneous generation of synthetic lymph nodes for the in vivo production of CAR-TaNK cells. Presented at: 7th Annual CAR-TCR Summit 2022, September 19-22, Boston, Massachusetts.
Recent Videos
Steve Kanner, PhD, the chief scientific officer of Caribou Biosciences
David Dimmock, MBBS, on AI-Guided ASO Development for Ultra-Rare Diseases
Manali Kamdar, MD, on The Importance of Bringing Liso-Cel to Earlier Lines of Lymphoma Treatment
Subhash Tripathi, PhD, on Generating In Vivo CARs With A2-CAR-CISC EngTreg Cells
Luke Roberts, MBBS, PhD, on Challenges in Developing Gene Therapy for Heart Failure
Steve Kanner, PhD, the chief scientific officer of Caribou Biosciences
Paul Y. Song, MD, the chairman and chief executive officer of NKGen
Lisa Nieland on Slowing Tumor Growth in Glioblastoma With Novel AAV Therapy
Manali Kamdar, MD, on Acclimating to Routine CAR T Practice in the Field
Paul Y. Song, MD, the chairman and chief executive officer of NKGen
© 2024 MJH Life Sciences

All rights reserved.